SL
Silence Therapeutics plc
SLN · NASDAQ
$12.50 -0.24% (-$0.03)
1M -11.35%
Market Cap $590.4M
P/E Ratio -
Div. Yield -
ROE 106.90%
Piotroski F-Score Weak
1/9Valuation
0 /100
Expensive P/S 961.15x
P/B 15.35x
P/E N/A
Growth
22 /100
Declining Rev. growth 68.36%
Book val. growth 41.33%
EPS growth N/A
Profitability
20 /100
Weak Gross margin 51.00%
FCF margin 6,893.22%
Net margin 9,755.61%
Quality
0 /100
Poor ROIC 176.21%
Asset turnover 0.01x
ROE 106.90%
Debt
33 /100
High Debt/Equity -0.00x
Current ratio 7.42x
Int. coverage N/A
Stability
41 /100
Moderate Beta 1.41x
Profitable years 0
Rev. volatility 90.95%
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na SLN
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Iain Gladstone Ross
Employees
88
Headquarters
London
Nadcházející události
05 LIS
Earnings
Upcoming earnings report